ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2424

Investigation Of The Role Of Histone Deacetylases In Rheumatoid Arthritis Synovial Fibroblasts

Sarah Hawtree1, Munitta Muthana1, Sarah Aynsley1, J. Mark Wilkinson2 and Anthony G. Wilson3, 1Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, 2Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, United Kingdom, 3Infection & Immunity, University of Sheffield, Sheffield, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Epigenetics, Histone Modification, rheumatoid arthritis (RA) and synovial cells, synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Rheumatoid arthritis (RA) is a chronic, autoimmune, inflammatory disease that affects synovial joints. A key characteristic of RA is hyperplasia of fibroblast-like synoviocytes (FLS). These FLS develop an aggressive phenotype that augments tissue destruction and it is not currently known how their phenotype is stably maintained, however epigenetic changes have been implicated. Histone deacetylases (HDACs) are key enzymes that contribute to the epigenetic signature through changes in the acetylation status of histones. Recent studies have reported conflicting evidence of HDAC activity in RA synovium and FLS; however promising results were obtained using HDAC inhibitors in murine arthritis models and human juvenile arthritis. Further investigations into the specific role of individual HDACs in RA are required and may allow discovery of more specific therapeutic targets. Our aim is to determine the role of HDACs in maintaining the autoaggressive phenotype of RA FLS.

Methods:

Fresh synovial biopsies obtained from RA and osteoarthritis (OA) patients were used to isolate FLS following digestion with collagenase-1. Real time-qPCR (RT-qPCR) was used to assess the levels of HDAC1-11 in RA FLS compared to OA FLS. To determine the cellular localization of HDACs, sections from patient arthroscopies were co-stained with anti-HDACs and anti-fibroblast antibody. In addition, HDACs and a non-targeting control (NTC) were knocked down in FLS using siRNA transfection; this was confirmed by RT-qPCR and western blotting. Cell viability after knockdown was assessed by flow cytometry using annexin V/propidium iodide dual staining. Cell invasion and migration after knock down were assessed using a matrigel invasion assay and a scratch assay, respectively.

Results:

The mRNA levels of HDACs 1-11 are higher in RA compared to OA, with HDAC1 levels showing the greatest difference (4.3-fold higher). A 65% knockdown of HDAC1 (HDAC1KD) mRNA was achieved using siRNA compared to a NTC (n=3 patients) and this did not affect cell viability (n=6) (>95.5% viable HDACKD cells vs. >95% viable NTC cells).  Using the matrigel invasion assay we found that HDAC1KD reduced the number of FLS invading the Matrigel (p=0.02) compared to the NTC (n=6). Also HDACKD reduced the number of FLS migrating (p=0.01) compared to the NTC (n=6).

Conclusion:

HDAC1 expression is increased in RA FLS compared to OA FLS. Knocking down HDAC1 in RA FLS does not affect cell viability but does reduce their ability to invade and migrate, suggesting that HDAC1 may contribute to the invasiveness and migration potential of RA FLS. Further work will determine the effects of HDAC1 knockdown in FLS on proliferation and the expressed genome.


Disclosure:

S. Hawtree,
None;

M. Muthana,
None;

S. Aynsley,
None;

J. M. Wilkinson,
None;

A. G. Wilson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigation-of-the-role-of-histone-deacetylases-in-rheumatoid-arthritis-synovial-fibroblasts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology